PolyActiva presents positive clinical trial results
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting - March 2022
PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
PolyActiva commences its first Phase I clinical trial.
PolyActiva raises AUD$9.2M in Series B venture funding.
© 2023 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US